REDEMPLO approved and commercially accelerating; the bet is whether Phase 3 sHTG data earns a label expansion into a market dwarfing FCS

Arrowhead Pharmaceuticals is a commercial-stage company with REDEMPLO, an approved targeted therapy for familial chylomicronemia syndrome that reduces dangerously high blood triglycerides, and it is now seeking regulatory approval to expand the drug's use into the much larger patient population with severe hypertriglyceridemia.

REDEMPLO (plozasiran) launched in FCS with Phase 3 SHASTA-3/4 data showing 79-81% triglyceride reductions and a 78% acute pancreatitis reduction in severe hypertriglyceridemia, a population many times larger than the approved indication. The thesis hinges on whether the sNDA converts those results into an approved label expansion, with a priority review voucher compressing the review clock. The principal risk is regulatory: pancreatitis reduction derived from a broad sHTG population rather than a placebo-controlled outcomes trial may not satisfy FDA's standard for a clinical benefit claim on the label.